The PARAGON-HF trial reported a highly significant treatment-by-sex interaction, with women showing a greater decrease in cardiovascular death and hospitalization for HF than men when treated with a neprilysin inhibitor (treatment-by-sex interaction, P =0.021). 8 Furthermore, that trial reported a meaningful treatment–by–sex–by–ejection fraction interaction; that is, women showed a more favorable treatment effect than men up to higher values for ejection fraction (eg, ejection fractions between 55% and 60%).
← all excerpts
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
1
—
—